The prescribing information for Tri-Luma (fluocinolone acetonide 0.01%, hydroquinone 4%, tretinoin 0.05%, per its Drugs@FDA record) describes the cream as indicated for the short-term treatment of moderate to severe melasma of the face, in the presence of measures for sun avoidance, including the use of sunscreens. This guide sets out what labels and a consensus abstract say about sunscreen and sun avoidance, and where that evidence stops.
What the Tri-Luma label and leaflet say
The dosage section of the Tri-Luma label (fluocinolone acetonide 0.01%, hydroquinone 4%, tretinoin 0.05%) says: during the day, use a sunscreen of SPF 30, wear protective clothing, and avoid sunlight exposure. The patient counseling section states that sunscreen use is an essential aspect of melasma therapy, as even minimal sunlight sustains melanocytic activity.
The patient information leaflet for Tri-Luma (fluocinolone acetonide 0.01%, hydroquinone 4%, tretinoin 0.05%) adds that patients should avoid sunlight, sunlamps, tanning beds, and ultraviolet light during treatment with the cream. These are instructions written for that one product. They are repeated here as the label's words, not as advice.
What a hydroquinone 4% label says
The patient information section of a prescription hydroquinone USP 4% skin bleaching cream label says that, to prevent repigmentation during treatment and maintenance therapy, sun exposure on treated skin should be avoided by application of a broad spectrum sunscreen (SPF 15 or greater) or by use of protective clothing. The clinical pharmacology section of the same label states that exposure to sunlight or ultraviolet light will cause repigmentation of bleached areas.
The two labels name different SPF figures: SPF 30 for Tri-Luma and SPF 15 or greater for the hydroquinone 4% cream label. Each is the wording of its own label.
What a consensus abstract says
A Delphi consensus of dermatologists convened under the Pigmentary Disorders Society reports that its key recommendations highlighted photoprotection with broad-spectrum sunscreens as essential. That is described here only as far as the abstract goes.
A pregnancy sunscreen study and its limits
A clinical trial of a broad-spectrum sunscreen in pregnant women compared its results with a previous usual-condition study by the same investigators, not with a concurrent control group described in the abstract. Of 185 patients who completed the study, only five new cases of chloasma were noted, an occurrence of 2.7%, versus 53% previously observed.
This is an observational comparison, so it cannot show cause and effect. It measured new chloasma in pregnancy. It did not measure whether melasma comes back.
What this does not tell you
The sources used here report no trial of hydroquinone 8% or of the four-ingredient blend with tretinoin, niacinamide and vitamin C, so label wording for Tri-Luma or for a hydroquinone 4% cream cannot be assumed to apply to other strengths or blends. The labels give instructions, not measured results: none of the sources above reports how much a given sunscreen, SPF number or habit changes any outcome in people using hydroquinone. The consensus is an abstract, and the pregnancy study looked at a different question. A licensed provider decides what sun protection fits a person.